I'm still quite bullish on the biotech theme for Q4.
Textbook pattern playing out on $ARKG ETF as it stair-steps in an uptrend.
Doesn't mean there won't be red days, but as long as the overall trajectory is upwards, buying dips on higher-beta names should pay off.